A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension

Am J Hypertens. 2004 Nov;17(11 Pt 1):1056-8. doi: 10.1016/j.amjhyper.2004.06.018.

Abstract

Background: Many patients seek complementary medicine treatments like neutraceuticals for common conditions such as hypertension.

Methods: We conducted a placebo-controlled prospective randomized crossover study in 10 hypertensive subjects to determine whether a single dose of a hydrolysate of bovine milk protein (designated C12 peptide; low and high dose), either alone or combined with alginic acid (low and high dose), reduced daytime blood pressure (BP), as determined by ambulatory BP monitoring.

Results: Within the five treatment regimens a significant reduction of 9.2 +/- 3.2 mm Hg in systolic BP at h 6 compared with h 2 occurred on the higher dose of alginic acid (1754 mg) combined with C12 (P = .02). The C12 peptide with the higher dose of alginic acid also showed a significant reduction of 6.0 +/- 2.0 mm Hg in diastolic BP at h 6 compared with h 2 (P = .015).

Conclusions: These preliminary data are encouraging and deserve testing in a larger and longer treatment trial.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alginates / therapeutic use
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure / drug effects
  • Blood Pressure Monitoring, Ambulatory
  • Caseins / therapeutic use*
  • Complementary Therapies
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Glucuronic Acid / therapeutic use
  • Hexuronic Acids / therapeutic use
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Alginates
  • Antihypertensive Agents
  • Caseins
  • Hexuronic Acids
  • casein hydrolysate
  • Glucuronic Acid